Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT06997081Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Sep 2025
- Primary completion
- Sep 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by University of Miami. Primary endpoint: Minimal residual disease (10^-5 sensitivity) up to 2 years. Started Sep 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06997081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997081.